Physician profile
Christopher Vare
NPI 1558688986
$4,861.19
in general payments reported to CMS, 2019-2025
41 companies · $801 in 2025
The $801 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,032 · 2020: $615 · 2021: $385 · 2022: $616 · 2023: $524 · 2024: $889 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,214.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,213.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,226.11 | 2021-2025 | Vraylar, Ubrelvy |
| Lilly USA, LLC | $591.55 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novo Nordisk INC | $580.46 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $328.92 | 2019-2020 | |
| Axsome Therapeutics, INC. | $275.42 | 2024 | Auvelity |
| Astellas Pharma US INC | $173.53 | 2019-2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $170.41 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $113.28 | 2019-2022 | |
| Bausch Health US, LLC | $112.76 | 2019-2025 | Aplenzin, Wellbutrin |
| Merck Sharp & Dohme LLC | $108.42 | 2019-2023 | Vaxneuvance, Gardasil 9 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $92.58 | 2019-2025 | Xifaxan |
| Pfizer INC. | $87.47 | 2019-2025 | |
| Kowa Pharmaceuticals America, INC. | $83.08 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $70.66 | 2020-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $69.99 | 2019-2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Vare listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.